NasdaqGM - Delayed Quote USD

Fate Therapeutics, Inc. (FATE)

3.8000 -0.0700 (-1.81%)
At close: April 26 at 4:00 PM EDT
3.8800 +0.08 (+2.11%)
After hours: April 26 at 5:42 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
63,533.0000
63,533.0000
96,300.0000
55,846.0000
31,434.0000
Operating Expense
254,044.0000
254,044.0000
404,686.0000
272,840.0000
159,519.0000
Operating Income
-190,511.0000
-190,511.0000
-308,386.0000
-216,994.0000
-128,085.0000
Net Non Operating Interest Income Expense
17,186.0000
17,186.0000
5,842.0000
1,309.0000
2,400.0000
Other Income Expense
12,397.0000
12,397.0000
20,823.0000
3,534.0000
-47,702.0000
Pretax Income
-160,928.0000
-160,928.0000
-281,721.0000
-212,151.0000
-173,387.0000
Net Income Common Stockholders
-160,928.0000
-160,928.0000
-281,721.0000
-212,151.0000
-173,387.0000
Diluted NI Available to Com Stockholders
-160,928.0000
-160,928.0000
-281,721.0000
-212,151.0000
-173,387.0000
Basic EPS
-1.64
-1.64
-2.91
-2.24
-2.10
Diluted EPS
-1.64
-1.64
-2.91
-2.24
-2.10
Basic Average Shares
98,411.1620
98,411.1620
96,826.0580
94,747.3110
82,385.3190
Diluted Average Shares
98,411.1620
98,411.1620
96,826.0580
94,747.3110
82,385.3190
Total Operating Income as Reported
-190,511.0000
-190,511.0000
-308,386.0000
-216,994.0000
-128,085.0000
Total Expenses
254,044.0000
254,044.0000
404,686.0000
272,840.0000
159,519.0000
Net Income from Continuing & Discontinued Operation
-160,928.0000
-160,928.0000
-281,721.0000
-212,151.0000
-173,387.0000
Normalized Income
-163,443.0000
-163,443.0000
-302,028.0000
-215,685.0000
-125,685.0000
Interest Income
17,186.0000
17,186.0000
5,842.0000
1,309.0000
2,400.0000
Net Interest Income
17,186.0000
17,186.0000
5,842.0000
1,309.0000
2,400.0000
EBIT
-190,511.0000
-190,511.0000
-308,386.0000
-216,994.0000
-128,085.0000
EBITDA
-172,229.0000
-172,229.0000
-294,628.0000
-211,144.0000
-124,998.0000
Reconciled Depreciation
18,282.0000
18,282.0000
13,758.0000
5,850.0000
3,087.0000
Net Income from Continuing Operation Net Minority Interest
-160,928.0000
-160,928.0000
-281,721.0000
-212,151.0000
-173,387.0000
Total Unusual Items Excluding Goodwill
2,515.0000
2,515.0000
20,307.0000
3,534.0000
-47,702.0000
Total Unusual Items
2,515.0000
2,515.0000
20,307.0000
3,534.0000
-47,702.0000
Normalized EBITDA
-174,744.0000
-174,744.0000
-314,935.0000
-214,678.0000
-77,296.0000
12/31/2020 - 10/1/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALLO Allogene Therapeutics, Inc.
2.8900
+1.23%
 
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%
 
NKTX Nkarta, Inc.
6.87
+0.73%
 
SANA Sana Biotechnology, Inc.
8.72
+2.59%
 
BEAM Beam Therapeutics Inc.
21.38
-1.02%
 
FGEN FibroGen, Inc.
1.0400
+1.96%
 
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
 
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
CRBU Caribou Biosciences, Inc.
3.7100
-1.33%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%